Comparative Study of Specular Microscopes for Measurements of Cell Density, Coefficient of Variation and Hexagonality
Launched by NIDEK CO. LTD. · Oct 24, 2014
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
The primary objective of this clinical study is to collect clinical data to support an FDA 510(k) submission for the Nidek CEM-530 Center point method and Corner point method.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Non-Pathologic: Male or female subjects from 18 to 80 years old who have full legal capacity to volunteer on the date the informed consent is signed. Subjects who can follow the instructions by the clinical staff at the clinical site,and can attend examinations on the scheduled examination date. Subjects who agree to participate in the study.
- * Pathologic: Male and female subjects from 29 to 80 years old who have full legal capacity to volunteer on the date the informed consent is signed. Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date. Subjects who agree to participate in the study. At least one eye with any of the following conditions:
- • History of post-op surgical trauma including bullous keratopathy
- • History of corneal transplant
- • Physical injury or trauma to the cornea
- • Long term Fuch's dystrophy, Guttata or other corneal endothelial dystrophies
- • Keratoconus
- • Long term PMMA contact lens use (greater than 3 years)
- Exclusion Criteria:
- * Non-Pathologic: Male and female subjects from 29 to 80 years old who have full legal capacity to volunteer on the date the informed consent is signed. Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date. Subjects who agree to participate in the study. At least one eye with any of the following conditions:
- • History of post-op surgical trauma including bullous keratopathy
- • History of corneal transplant
- • Physical injury or trauma to the cornea
- • Long term Fuch's dystrophy, Guttata or other corneal endothelial dystrophies
- • Keratoconus
- • Long term PMMA contact lens use (greater than 3 years)
- • Pathologic: History of cataract, refractive or ocular surgical procedures that render the cornea opaque or otherwise impact its ability to be imaged using the investigational device. Fixation problems which may prevent obtaining at least poor quality (refer to Figure 1) CEM-530 and KONAN CELLCHEK PLUS images in either eye.
About Nidek Co. Ltd.
Nidek Co., Ltd. is a leading global manufacturer and developer of advanced optical and medical equipment, specializing in innovative solutions for vision care and ophthalmic diagnostics. With a commitment to enhancing patient outcomes through cutting-edge technology, Nidek offers a comprehensive range of products, including laser systems, diagnostic instruments, and surgical devices. The company is dedicated to advancing research and clinical trials that support the development of effective treatments for various ocular conditions, ensuring the highest standards of quality and reliability in its offerings. Nidek's expertise and focus on innovation position it as a key player in the ophthalmic industry, contributing significantly to the improvement of eye health worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Andover, Massachusetts, United States
Patients applied
Trial Officials
Gail Torkildsen, MD
Principal Investigator
Andover Eye Associates
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials